An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of combining durvalumab
with EP followed by durvalumab + olaparib maintenance therapy as first-line treatment in
patients with extensive-disease small-cell lung cancer (SCLC).